Abstract
Type 2 diabetes mellitus (T2DM) is characterized by poor insulin secretion from pancreatic beta cells together with reduced insulin sensitivity of adipose tissue, liver, and muscle. This results in an improper response to fasting and refeeding, and hyperglycemia causing acute and chronic complications associated with T2DM. The International Diabetes Federation estimates that there are 537 million adults aged 20–79 with diabetes in 2021 and this number is projected to rise to 643 million by 2030. The incidence of T2DM is largely driven by obesity pandemic and is increasing at alarming rates. In the development and progression of T2DM, the primary role of environmental factors such as smoking, poor diet, and sedentary lifestyle is well known. Genetic susceptibility has also been studied, and many genes that determine the hormonal regulation of glucose and lipid metabolism have been found to be associated with T2DM. The human gut microbiota can be considered an organ with important functions for human metabolism, digestion, maintenance of the intestinal barrier function, and immunomodulation. It helps to modulate host metabolism and its change appears to be related to the development of T2DM and cardiometabolic disorders associated with overweight and obesity.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Allin KH, Tremaroli V, Caesar R, Jensen BAH, Damgaard MTF, Bahl MI, et al. Aberrant intestinal microbiota in individuals with prediabetes. Diabetologia. 2018;61:810–20. https://doi.org/10.1007/s00125-018-4550-1.
Arora T, Vanslette AM, Hjorth SA, Bäckhed F. Microbial regulation of enteroendocrine cells. Med. 2021;2:553–70. https://doi.org/10.1016/j.medj.2021.03.018.
Attaye I, Pinto-Sietsma SJ, Herrema H, Nieuwdorp M. A crucial role for diet in the relationship between gut microbiota and cardiometabolic disease. Annu Rev Med. 2020;71:149–61. https://doi.org/10.1146/annurev-med-062218-023720.
Aydin Ö, Nieuwdorp M, Gerdes V. The gut microbiome as a target for the treatment of type 2 diabetes. Curr Diab Rep. 2018;18:55. https://doi.org/10.1007/s11892-018-1020-6.
Baxter M, Colville A. Adverse events in faecal microbiota transplant: a review of the literature. J Hosp Infect. 2016;92:117–27. https://doi.org/10.1016/j.jhin.2015.10.024.
Bennett BJ, de Aguiar Vallim TQ, Wang Z, Shih DM, Meng Y, Gregory J, et al. Trimethylamine N-oxide, a metabolite associated with atherosclerosis, exhibits complex genetic and dietary regulation. Cell Metab. 2013;17:49–60. https://doi.org/10.1016/j.cmet.2012.12.011.
Brial F, Alzaid F, Sonomura K, Kamatani Y, Meneyrol K, Le Lay A, et al. The natural metabolite 4-cresol improves glucose homeostasis and enhances β-cell function. Cell Rep. 2020;30:2306–20. https://doi.org/10.1016/j.celrep.2020.01.066.
Caesar R, Fak F, Backhed F. Effects of gut microbiota on obesity and atherosclerosis via modulation of inflammation and lipid metabolism. J Intern Med. 2010;268:320–8. https://doi.org/10.1111/j.1365-2796.2010.02270.x.
Caesar R, Reigstad CS, Backhed HK, Reinhardt C, Ketonen M, Lundén GO, et al. Gut-derived lipopolysaccharide augments adipose macrophage accumulation but is not essential for impaired glucose or insulin tolerance in mice. Gut. 2012;61:1701–7. https://doi.org/10.1136/gutjnl-2011-301689.
Caesar R, Tremaroli V, Kovatcheva-Datchary P, Cani PD, Bäckhed F. Crosstalk between gut microbiota and dietary lipids aggravates WAT inflammation through TLR signaling. Cell Metab. 2015;22:658–68. https://doi.org/10.1016/j.cmet.2015.07.026.
Callender C, Attaye I, Nieuwdorp M. The interaction between the gut microbiome and bile acids in cardiometabolic diseases. Meta. 2022;12:65. https://doi.org/10.3390/metabo12010065.
Cani PD, Dewever C, Delzenne NM. Inulin-type fructans modulate gastrointestinal peptides involved in appetite regulation (glucagon-like peptide-1 and ghrelin) in rats. Br J Nutr. 2007a;92:521. https://doi.org/10.1079/bjn20041225.
Cani PD, Neyrinck AM, Tuohy KM, Fava F, Gibson GR, Knauf C, et al. Changes in gut microflora are responsible for high-fat diet-induced diabetes through a mechanism associated with endotoxaemia. Diabetologia. 2007b;50:S68–8. https://doi.org/10.2337/db07-1403.
Cano PG, Santacruz A, Moya Á, Sanz Y. Bacteroides uniformis CECT 7771 ameliorates metabolic and immunological dysfunction in mice with high-fat-diet induced obesity. PLoS One. 2012;7:e41079. https://doi.org/10.1371/journal.pone.0041079.
Chávez Talavera O, Tailleux A, Lefebvre P, Staels B. Bile acid control of metabolism and inflammation in obesity, type2 diabetes, dyslipidemia, and nonalcoholic fatty liver disease. Gastroenterology. 2017;152:1679–94. https://doi.org/10.1053/j.gastro.2017.01.055.
Chelakkot C, Choi Y, Kim DK, Park HT, Ghim J, Kwon Y, et al. Akkermansia muciniphila-derived extracellular vesicles influence gut permeability through the regulation of tight junctions. Exp Mol Med. 2018;50:e450. https://doi.org/10.1038/emm.2017.282.
Chen SF, Henderson A, Petriello MC, Romano KA, Gearing M, Miao J, et al. Trimethylamine N-oxide binds and activates PERK to promote metabolic dysfunction. Cell Metab. 2019;30:1141–1151.e5. https://doi.org/10.1016/j.cmet.2019.08.021.
Cotillard A, Kennedy SP, Kong LC, Prifti E, Pons N, Le Chatelier E, et al. Dietary intervention impact on gut microbial gene richness. Nature. 2013;500:585–8. https://doi.org/10.1038/nature12480.
de Mello VD, Paananen J, Lindström J, Lankinen MA, Shi L, Kuusisto J, et al. Indolepropionic acid and novel lipid metabolites are associated with a lower risk of type 2 diabetes in the Finnish diabetes prevention study. Sci Rep. 2017;7:46337. https://doi.org/10.1038/srep46337.
Dostal A, Chassard C, Hilty FM, Zimmermann MB, Jaeggi T, Rossi S, et al. Iron depletion and repletion with ferrous sulfate or electrolytic iron modifies the composition and metabolic activity of the gut microbiota in rats. J Nutr. 2012;142:271–7. https://doi.org/10.3945/jn.111.148643.
Doumatey AP, Adeyemo A, Zhou J, Lei L, Adebamowo SN, Adebamowo C, et al. Gut microbiome profiles are associated with type 2 diabetes in urban Africans. Front Cell Infect Microbiol. 2020;10:63. https://doi.org/10.3389/fcimb.2020.00063.
Du L, Li Q, Yi H, Kuang T, Tang Y, Fan G. Gut microbiota-derived metabolites as key actors in type 2 diabetes mellitus. Biomed Pharmacother. 2022;149:112839. https://doi.org/10.1016/j.biopha.2022.112839.
Emoto T, Yamashita T, Sasaki N, Hirota Y, Hayashi T, So A, et al. Analysis of gut microbiota in coronary artery disease patients: a possible link between gut microbiota and coronary artery disease. J Atheroscler Thromb. 2016;23:908–21. https://doi.org/10.5551/jat.32672.
Fang S, Suh JM, Reilly SM, Yu E, Osborn O, Lackey D, et al. Intestinal FXR agonism promotes adipose tissue browning and reduces obesity and insulin resistance. Nat Med. 2015;21:159–65. https://doi.org/10.1038/nm.3760.
Figuero E, Sanchez-Beltran M, Cuesta-Frechoso S, Tejerina JM, del Castro JA, Gutiérrez JM, et al. Detection of periodontal bacteria in atheromatous plaque by nested polymer- ase chain reaction. J Periodontol. 2011;82:1469–77. https://doi.org/10.1902/jop.2011.100719.
Gao X, Liu XF, Xu J, Xue CH, Xue Y, Wang YM. Dietary trimethylamine N- oxide exacerbates impaired glucose tolerance in mice fed a high fat diet. J Biosci Bioeng. 2014;118:476–81. https://doi.org/10.1016/j.jbiosc.2014.03.001.
Gao R, Zhu C, Li H, Yin M, Pan C, Huang L, et al. Dysbiosis signatures of gut microbiota along the sequence from healthy, young patients to those with overweight and obesity. Obesity. 2018;26:351–61. https://doi.org/10.1002/oby.22088.
Gurung M, Li Z, You H, Rodrigues R, Jump D, Morgun, et al. Role of gut microbiota in type 2 diabetes pathophysiology. EBioMedicine. 2020;51:102590. https://doi.org/10.1016/j.ebiom.2019.11.051.
Herrema H, Niess JH. Intestinal microbial metabolites in human metabolism and type 2 diabetes. Diabetologia. 2020;63:2533–47. https://doi.org/10.1007/s00125-020-05268-4.
Hoffmann TW, Pham HP, Bridonneau C, Aubry C, Lamas B, Martin-Gallausiaux C, et al. Microorganisms linked to inflammatory bowel disease- associated dysbiosis differentially impact host physiology in gnotobiotic mice. ISME J. 2016;10:460–77. https://doi.org/10.1038/ismej.2015.127.
International Diabetes Federation. IDF Diabetes atlas. 10th ed, https://diabetesatlas.org/; 2021.
Jie Z, Xia H, Zhong SL, Li S, Liang S, Zhong H, et al. The gut microbiome in atherosclerotic cardiovascular disease. Nat Commun. 2017;8:845. https://doi.org/10.1038/s41467-017-00900-1.
Kimura I, Ozawa K, Inoue D, Imamura T, Kimura K, Maeda T, et al. The gut microbiota suppresses insulin-mediated fat accumulation via the short-chain fatty acid receptor GPR43. Nat Commun. 2013;4:1829. https://doi.org/10.1038/ncomms2852.
Kinoshita M, Suzuki Y, Saito Y. Butyrate reduces colonic paracellular permeability by enhancing PPAR-gamma activation. Biochem Biophys Res Commun. 2002;293:827–31. https://doi.org/10.1016/S0006-291X(02)00294-2.
Kootte RS, Levin E, Salojarvi J, Smits LP, Hartstra AV, Udayappan SD, et al. Improvement of insulin sensitivity after lean donor feces in metabolic syndrome is driven by baseline intestinal microbiota composition. Cell Metab. 2017;26:611–9.e6. https://doi.org/10.1016/j.cmet.2017.09.008.
Kwan SY, Jiao J, Qi J, Wang Y, Wei P, McCormick JB, et al. Bile acid changes associated with liver fibrosis and steatosis in the Mexican American population of South Texas. Hepatol Commun. 2020;4:555–68. https://doi.org/10.1002/hep4.1490.
Lever M, George PM, Slow S, Bellamy D, Young JM, Ho M, et al. Betaine and trimethylamine-N-oxide as predictors of cardiovascular outcomes show different patterns in diabetes mellitus: an observational study. PLoS One. 2014;9:e114969. https://doi.org/10.1371/journal.pone.0114969.
Ley RE, Backhed F, Turnbaugh P, Lozupone CA, Knight RD, Gordon JI. Obesity alters gut microbial ecology. Proc Natl Acad Sci U S A. 2005;102:11070–5. https://doi.org/10.1073/pnas.0504978102.
Liu Y, Wang Y, Ni Y, Cheung CKY, Lam KSL, Wang Y, et al. Gut microbiome fermentation determines the efficacy of exercise for diabetes prevention. Cell Metab. 2020;31:77–91.e5. https://doi.org/10.1016/j.cmet.2019.11.001.
Massey W, Brown JM. The gut microbial endocrine organ in type 2 diabetes. Endocrinology. 2021;162:1–14. https://doi.org/10.1210/endocr/bqaa235.
Munukka E, Rintala A, Toivonen R, Nylund M, Yang B, Takanen A, et al. Faecalibacterium prausnitzii treatment improves hepatic health and reduces adipose tissue inflammation in high-fat fed mice. ISME J. 2017;11:1667–79. https://doi.org/10.1038/ismej.2017.24.
Murphy R, Tsai P, Jüllig M, Liu A, Plank L, Booth M. Differential changes in gut microbiota after gastric bypass and sleeve gastrectomy bariatric surgery vary according to diabetes remission. Obes Surg. 2017;27:917–25. https://doi.org/10.1007/s11695-016-2399-2.
Patel A, Thompson A, Abdelmalek L, Adams-Huet B, Jialal I. The relationship between tyramine levels and inflammation in metabolic syndrome. Horm Mol Biol Clin Invest. 2019;40:20190047. https://doi.org/10.1515/hmbci-2019-0047.
Pedersen HK, Nielsen HB, Hyotylainen T, Nielsen T, Jensen BA, et al. Human gut microbes impact host serum metabolome and insulin sensitivity. Nature. 2016;535:376–81. https://doi.org/10.1038/nature18646.
Portincasa P, Bonfrate L, Vacca M, De Angelis M, Farella I, Lanza E, et al. Gut microbiota and short chain fatty acids: implications in glucose homeostasis. Int J Mol Sci. 2022;23:1105. https://doi.org/10.3390/ijms23031105.
Qin J, Li Y, Cai Z, Shenghui L, Zhu J, Zhang F, et al. A metagenome-wide association study of gut microbiota in type 2 diabetes. Nature. 2012;490:55–60. https://doi.org/10.1038/nature11450.
Régnier M, Van Hul M, Knauf C, Cani PD. Gut microbiome, endocrine control of gut barrier function and metabolic diseases. J Endocrinol. 2021;248:2. https://doi.org/10.1530/JOE-20-0473.
Reimer RA, Grover GJ, Koetzner L, Gahler RJ, Lyon MR, Wood S. Combining sitagliptin/metformin with a functional fiber delays diabetes progression in zucker rats. J Endocrinol. 2014;220:361–73. https://doi.org/10.1530/JOE-13-0484.
Rondanelli M, Gasparri C, Peroni G, Faliva MA, Naso M, Perna S, et al. The potential roles of very low calorie, very low-calorie ketogenic diets and very low carbohydrate diets on the gut microbiota composition. Front Endocrinol. 2021;12:518. https://doi.org/10.3389/fendo.2021.662591.
Salamon D, Sroka-Oleksiak A, Kapusta P, Szopa M, Mrozińska S, Ludwig-Słomczyńska AH, et al. Characteristics of gut microbiota in adult patients with type 1 and type 2 diabetes based on next generation sequencing of the 16S rRNA gene fragment. Pol Arch Intern Med. 2018;128:336–43. https://doi.org/10.20452/pamw.4246.
Sanna S, van Zuydam NR, Mahajan A, Kurilshikov A, Vich Vila A, Vosa U, et al. Causal relationships among the gut microbiome, short-chain fatty acids and metabolic diseases. Nat Genet. 2019;51:600–5. https://doi.org/10.1038/s41588-019-0350-x.
Sasaki M, Ogasawara N, Funaki Y, Mizuno M, Iida A, Goto C, et al. Transglucosidase improves the gut microbiota profile of type 2 diabetes mellitus patients: a randomized double-blind, placebo-controlled study. BMC Gastroenterol. 2013;13:81. https://doi.org/10.1186/1471-230X-13-81.
Scheithauer TPM, Rampanelli E, Nieuwdorp M, Vallance BA, Verchere CB, van Raalte DH, et al. Gut microbiota as a trigger for metabolic inflammation in obesity and type 2 diabetes. Front Immunol. 2020;11:571731. https://doi.org/10.3389/fimmu.2020.571731.
Schwiertz A, Taras D, Schafer K, Beijer S, Bos NA, Donus C, et al. Microbiota and SCFA in lean and overweight healthy subjects. Obesity (Silver Spring). 2010;18:190–5. https://doi.org/10.1038/oby.2009.167.
Seldin MM, Meng Y, Qi H, Zhu WF, Wang Z, Hazen SL, et al. Trimethylamine N-oxide promotes vascular inflammation through signaling of mitogen-activated protein kinase and nuclear factor-kappaB. J Am Heart Assoc. 2016;5:e002767. https://doi.org/10.1161/JAHA.115.002767.
Shan ZL, Sun TP, Huang H, Chen SJ, Chen LK, Luo C, et al. Association between microbiota-dependent metabolite trimethylamine-N-oxide and type 2 diabetes. Am J Clin Nutr. 2017;106:888–94. https://doi.org/10.3945/ajcn.117.157107.
Spencer MD, Hamp TJ, Reid RW, Fischer LM, Zeisel SH, Fodor AA. Association between composition of the human gastrointestinal microbiome and development of fatty liver with choline deficiency. Gastroenterology. 2011;140:976–86. https://doi.org/10.1053/j.gastro.2010.11.049.
Stenman LK, Waget A, Garret C, Briand F, Burcelin R, Sulpice T, et al. Probiotic B420 and prebiotic polydextrose improve efficacy of antidiabetic drugs in mice. Diabetol Metab Syndr. 2015;7:75. https://doi.org/10.1186/s13098-015-0075-7.
Tang WH, Wang ZN, Li XS, Fan YY, Li DS, Wu YP, et al. Increased trimethylamine N-oxide portends high mortality risk independent of glycemic control in patients with type 2 diabetes mellitus. Clin Chem. 2017;63:297–306. https://doi.org/10.1373/clinchem.2016.263640.
Trabelsi MS, Daoudi M, Prawitt J, Ducastel S, Touche V, Sayin SI, et al. Farnesoid X receptor inhibits glucagon-like peptide-1 production by enteroendocrine L cells. Nat Commun. 2015;6:7629. https://doi.org/10.1038/ncomms8629.
Turnbaugh PJ, Ley RE, Mahowald MA, Magrini V, Mardis ER, Gordon JI. An obesity-associated gut microbiome with increased capacity for energy harvest. Nature. 2006;444:1027–31. https://doi.org/10.1038/nature05414.
Vrieze A, Van Nood E, Holleman F, Salojarvi J, Kootte RS, Bartelsman JF, et al. Transfer of intestinal microbiota from lean donors increases insulin sensitivity in individuals with metabolic syndrome. Gastroenterology. 2012;143:913–6.e7. https://doi.org/10.1053/j.gastro.2012.06.031.
Wang Z, Tang WH, Buffa JA, Fu X, Britt EB, Koeth RA, et al. Prognostic value of choline and betaine depends on intestinal microbiota-generated metabolite trimethylamine-N-oxide. Eur Heart J. 2014;35:904–10. https://doi.org/10.1093/eurheartj/ehu002.
Wang Z, Chen WD, Wang YD. Nuclear receptors: a bridge linking the gut microbiome and the host. Wang et al. Mol Med. 2021;27:144. https://doi.org/10.1186/s10020-021-00407-y.
Warmbrunn MV, Herrema H, Aron-Wisnewsky J, Soeters MR, Van Raalte DH, Nieuwdorp M. Gut microbiota: a promising target against cardiometabolic diseases. Expert Rev Endocrinol Metab. 2020;15:13–27. https://doi.org/10.1080/17446651.2020.1720511.
Watanabe H, Nakano T, Saito R, Akasaka D, Saito K, Ogasawara H, et al. Serotonin improves high fat diet induced obesity in mice. PLoS One. 2016;11:e0147143. https://doi.org/10.1371/journal.pone.0147143.
Zhang YQ, Lee FY, Barrera G, Lee H, Vales C, Gonzalez FJ, et al. Activation of the nuclear receptor FXR improves hyperglycemia and hyperlipidemia in diabetic mice. Proc Natl Acad Sci U S A. 2006;103:1006–11. https://doi.org/10.1073/pnas.0506982103.
Zhang X, Shen D, Fang Z, Jie Z, Qiu X, Zhang C, et al. Human gut microbiota changes reveal the progression of glucose intolerance. PLoS One. 2013;8:e71108. https://doi.org/10.1371/journal.pone.0071108.
Zheng J, Li H, Zhang X, Jiang M, Luo C, Lu Z, et al. Prebiotic mannan-oligosaccharides augment the hypoglycemic effects of metformin in correlation with modulating gut microbiota. J Agric Food Chem. 2018;66:5821–31. https://doi.org/10.1021/acs.jafc.8b00829.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2024 Springer Nature Switzerland AG
About this entry
Cite this entry
Longo, S., Menghini, R., Federici, M. (2024). Gut Microbiota and Type 2 Diabetes Mellitus. In: Federici, M., Menghini, R. (eds) Gut Microbiome, Microbial Metabolites and Cardiometabolic Risk. Endocrinology. Springer, Cham. https://doi.org/10.1007/978-3-031-35064-1_8
Download citation
DOI: https://doi.org/10.1007/978-3-031-35064-1_8
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-031-35063-4
Online ISBN: 978-3-031-35064-1
eBook Packages: MedicineReference Module Medicine